Level 3, 88 William Street, Perth WA 6000, Australia Telephone: +61 8 9463 2463 Facsimile: +61 8 9463 2499

31 July 2018

Australian Securities Exchange Level 40, Central Park 152-158 St Georges Terrace PERTH WA 6000

#### **APPENDIX 4C**

Attached is the Quarterly Report (Appendix 4C) for the quarter ended 30 June 2018.

The Company notes the cash balance at 30 June 2018 of ~ \$1,000. The Company is aware of the need for additional funding to ensure it remains in a position to continue its normal business activities and to ensure the realisation of assets and extinguishment of liabilities as and when they fall due and continues to work on funding options to address the above and to work towards lifting the current trading suspension in the Company's shares.

As announced to ASX on 23 July 2018, the Company issued 250,000 convertible notes with a face value of \$1.00 per note, raising \$250,000. As announced to ASX on 10 July 2018, the Company will use the proceeds as follows: for the purpose of transaction costs for the proposed 100% acquisition of Bio-Nexus Limited ("Proposed Transaction"); to part repay existing creditors; and to fund the ongoing working capital requirements of the Company. The Company continues to liaise with its existing creditors to agree forbearance and payment arrangements. In regards to the Company's largest creditor, Mr Ng (a former director) and his associates, the Company remains in negotiations with Mr Ng and his associates regarding revised repayment terms.

The Company notes that Bio-Nexus Limited has, in a binding manner, agreed to pay the reasonable costs of the Company directly incurred in connection with the Proposed Transaction.

The Directors also acknowledge their responsibility for ensuring that the Company does not trade insolvent.

On behalf of the Board

Henko Vos Company Secretary

+Rule 4.7B

# **Appendix 4C**

# Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

## Name of entity

Ephraim Resources Limited		
ABN	Quarter ended ("current quarter")	
63 008 666 233	30 June 2018	

Con	solidated statement of cash flows	Current quarter \$'000 AUD	Year to date (12 months) \$'000 AUD
1.	Cash flows from operating activities		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	-	(6)
	(f) administration and corporate costs	(12)	(46)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(12)	(52)

2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-

<sup>+</sup> See chapter 19 for defined terms

1 September 2016

Cons	solidated statement of cash flows	Current quarter \$'000 AUD	Year to date (12 months) \$'000 AUD
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Goldson transaction costs)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	11	40
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	11	40

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	2	13
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(12)	(52)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	11	40

<sup>+</sup> See chapter 19 for defined terms 1 September 2016

Con	solidated statement of cash flows	Current quarter \$'000 AUD	Year to date (12 months) \$'000 AUD
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	1	1

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$'000 AUD	Previous quarter \$'000 AUD
5.1	Bank balances	1	2
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1	2

6.	Payments to directors of the entity and their associates	Current quarter \$'000 AUD
6.1	Aggregate amount of payments to these parties included in item 1.2	-
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
N/A		

7.	Payments to related entities of the entity and their associates	Current quarter \$'000 AUD
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	
N/A		

+ See chapter 19 for defined terms 1 September 2016 Page 3

8.	Financing facilities available Add notes as necessary for an understanding of the position	Total facility amount at quarter end \$'000 AUD	Amount drawn at quarter end \$'000 AUD
8.1	Loan facilities	-	-
8.2	Credit standby arrangements	-	-
8.3	Other (please specify)	550	550
8.4	Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

<sup>+</sup> See chapter 19 for defined terms 1 September 2016

## LC Chew: A\$100,694

On 25 May 2016 the Company entered into a loan agreement with Chew Lee Ching, a related party of Mr Ng (a former director), for the advancement of SGD\$100,000 (A\$100,694) to the Company for working capital purposes. Under the revised terms of the loan agreement full repayment of the loan was required by 30 November 2017. The loan carries interest at 10% per annum, repayable at the end of the loan term. The Company sought to settle this loan through the conversion thereof into ordinary shares at the AGM held on 30 November 2017. The resolution did not receive approval by shareholders. The extension date was subsequently extended to 30 June 2018. The loan remains unpaid at 30 June 2018, with the parties in on-going negotiations regarding revised repayment options and terms.

## E Ng: A\$110,000

On 13 December 2016 the Company entered into a loan agreement with Mr Ng, for the advancement of A\$110,000 to the Company for working capital purposes. Under the revised terms of the loan agreement full repayment of the loan was required by 30 November 2017, unless shareholders approve the conversion of the loan into ordinary shares (the conversion rate to be the lower of \$0.001 per share (on a pre-consolidated basis) or 75% of the volume weighted average price of the Company's shares calculated over the 15 trading days on which trades in the shares were recorded immediately before the relevant shareholder's meeting). The loan carries interest at 20% per annum, repayable at the end of the loan term. The Company sought to settle this loan through the conversion thereof into ordinary shares at the AGM held on 30 November 2017. The resolution did not receive approval by shareholders. The extension date was subsequently extended to 30 June 2018. The loan remains unpaid at 30 June 2018, with the parties in on-going negotiations regarding revised repayment options and terms.

#### E Ng: A\$300,000

On 8 March 2017 Mr Ng settled a then payable loan balance owed by the Company, having previously provided a personal guarantee for the loan. The loan with Mr Ng was extended on the same terms as the loan he settled on the Company's behalf, being \$300,000 at an interest rate of 20% per annum payable on or before 30 November 2017. The extension date was subsequently extended to 30 June 2018. The loan remains unpaid at 30 June 2018, with the parties in on-going negotiations regarding revised repayment options and terms.

## E Ng: A\$15,032

On 14 August 2017 Mr Ng provided A\$15,032 to the Company for working capital. The advance remains unpaid at 30 June 2018, with the parties in on-going negotiations regarding revised repayment options and terms.

## E Ng: A\$14,068

On 23 February 2018 Mr Ng provided A\$14,068 to the Company for working capital. The advance remains unpaid at 30 June 2018, with the parties in on-going negotiations regarding revised repayment options and terms.

## Tanny Nee Ooi: A\$10,548

On 25 June 2018 Mrs Ooi provided A\$10,495 to the Company for working capital. The advance carries interest at NIL% per annum and is repayable by the earlier of the completion of the proposed Bio-Nexus Limited transaction or 31 December 2018.

1 September 2016

<sup>+</sup> See chapter 19 for defined terms

9.	Estimated cash outflows for next quarter	\$'000 AUD
9.1	Research and development	-
9.2	Product manufacturing and operating costs	-
9.3	Advertising and marketing	-
9.4	Leased assets	-
9.5	Staff costs	-
9.6	Administration and corporate costs	55
9.7	Other (100% acquisition of Bio-Nexus) *	271
9.8	Total estimated cash outflows	326

<sup>\* -</sup> As announced on the 10 July 2018, the Company announced it has signed a non-binding memorandum of understanding ("MOU") with Israeli technology company Bio-Nexus Limited to acquire 100% of the Bio-Nexus ("Transaction"). The transaction remains subject to a number of conditions, including relevant due diligence and approvals. Under the MOU, Bio-Nexus has however, in a binding manner, agreed to pay the reasonable costs of the Company directly incurred in connection with the Transaction.

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

## **Compliance statement**

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: (signed electronically)

Print name: Henko Vos (Company Secretary)

Date: 31 July 2018

## **Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose

1 September 2016

<sup>+</sup> See chapter 19 for defined terms

- additional information is encouraged to do so, in a note or notes included in or attached to this report.
- If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

1 September 2016 Page 7

<sup>+</sup> See chapter 19 for defined terms